Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
Guardant Health, Inc is a diagnostics & research business based in the US. Guardant Health shares (GH) are listed on the NASDAQ and all prices are listed in US Dollars. Guardant Health employs 622 staff and has a trailing 12-month revenue of around USD$257.6 million.
|Latest market close||USD$104.34|
|52-week range||USD$55.9 - USD$113.74|
|50-day moving average||USD$103.3912|
|200-day moving average||USD$87.9004|
|Wall St. target price||USD$116|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.281|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-25)||-7.37%|
|1 month (2020-11-06)||-7.63%|
|3 months (2020-09-04)||14.90%|
|6 months (2020-06-05)||25.38%|
|1 year (2019-12-05)||41.80%|
|2 years (2018-12-04)||145.74%|
|3 years (2017-12-02)||N/A|
|5 years (2015-12-02)||N/A|
|Revenue TTM||USD$257.6 million|
|Gross profit TTM||USD$143.7 million|
|Return on assets TTM||-7.47%|
|Return on equity TTM||-11.52%|
|Market capitalisation||USD$10.1 billion|
TTM: trailing 12 months
There are currently 2.4 million Guardant Health shares held short by investors – that's known as Guardant Health's "short interest". This figure is 6.3% up from 2.2 million last month.
There are a few different ways that this level of interest in shorting Guardant Health shares can be evaluated.
Guardant Health's "short interest ratio" (SIR) is the quantity of Guardant Health shares currently shorted divided by the average quantity of Guardant Health shares traded daily (recently around 894984.79087452). Guardant Health's SIR currently stands at 2.63. In other words for every 100,000 Guardant Health shares traded daily on the market, roughly 2630 shares are currently held short.
However Guardant Health's short interest can also be evaluated against the total number of Guardant Health shares, or, against the total number of tradable Guardant Health shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Guardant Health's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Guardant Health shares in existence, roughly 20 shares are currently held short) or 0.0344% of the tradable shares (for every 100,000 tradable Guardant Health shares, roughly 34 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Guardant Health.
Find out more about how you can short Guardant Health stock.
We're not expecting Guardant Health to pay a dividend over the next 12 months.
Over the last 12 months, Guardant Health's shares have ranged in value from as little as $55.9 up to $113.74. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Guardant Health's is 0.5024. This would suggest that Guardant Health's shares are less volatile than average (for this exchange).
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications. It also provides LUNAR-1 for minimal residual disease and recurrence detection in cancer survivors. In addition, the company is developing LUNAR-2 for early detection of cancer in higher risk individuals. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical trial referral, and liquid biopsy testing development and support services to biopharmaceutical companies and medical institutions. The company has collaboration agreement with Radius Health, Inc. to develop liquid biopsy companion diagnostic for elacestrant. Guardant Health, Inc. was incorporated in 2011 and is headquartered in Redwood City, California.
Everything we know about the Loha Co. IPO, plus information on how to buy in.
Everything we know about the Stem Inc IPO, plus information on how to buy in.
Everything we know about the View Inc IPO, plus information on how to buy in.
Everything we know about the Chime IPO, plus information on how to buy in.
Steps to owning and managing WPRT, with 24-hour and historical pricing before you buy.
Steps to owning and managing WBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing WLK, with 24-hour and historical pricing before you buy.
Steps to owning and managing WDC, with 24-hour and historical pricing before you buy.
Steps to owning and managing WAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing VSAT, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.